Accordingly, in an expanded clinical trial conducted in patients with different types of cancer treated with monoclonal antibody anti-PDL-1, the best tumor response was seen in those with high levels of PDL-1, which could help in making decisions regarding immunotherapy treatment [20], [38], Table 1. Here, CD274 is linked to cancer.